{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG002","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"20"}],"units":"Participants"}],"description":"-Defined as hypersensitivity reactions. Evaluated by physical exam, blood pressure, heart rate, respirations and temperature one hour prior to the infusion and then 15 minutes, 30 minutes, one hour, 2 hours, and 4 hours post-infusion","groups":[{"description":"* Day 1: Mobilization with 240 mcg/kg SC AMD3100 and leukopheresis\n* If PBSC collected are not adequate, then donor will again be mobilized with AMD3100 and have leukopheresis collection on day 3.","id":"OG000","title":"Subcutaneous (SC) Treatment Plan - Donor"},{"description":"* Conditioning Regimen\n\n  * Cyclophosphamide 60mg/kg/day on Days -3 and -2\n  * TBI 550cGy on Day -1\n* GVHD prophylaxis\n\n  \\*Cyclosporin 3.0mg/kg/day beginning on Day -1 then tapered through Day +100\n* PBSC transplant on Day 0","id":"OG001","title":"Recipients"},{"description":"* Day -3: Mobilization with 80-480 mcg/kg/day IV AMD3100 and PK analysis\n* Day 1: Mobilization with 240 mcg/kg/day SC AMD3100 and leukopheresis\n* If PBSC collected are not adequate, then donor will again be mobilized with AMD3100 and have leukopheresis collection on day 3.","id":"OG002","title":"Intravenous (IV) Treatment Plan - Donor"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Day +1 to +3 (SC donor arm) and Day -3 to +3 (IV donor arm)","title":"Proportion of Donors Who Experience Infusional Toxicity (Donor Only)","type":"SECONDARY","unitOfMeasure":"Participants"}